Drug Profile
Research programme: siRNA respiratory disorders therapeutics - GlaxoSmithKline/Sirna
Latest Information Update: 23 Mar 2010
Price :
$50
*
At a glance
- Originator Sirna Therapeutics
- Developer GlaxoSmithKline
- Class
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma; Respiratory syncytial virus infections; Respiratory tract disorders
Most Recent Events
- 29 Jan 2008 Preclinical development is ongoing
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
- 12 May 2006 Preclinical trials in Asthma in USA (unspecified route)